Skip to main content

Advertisement

Figure 2 | Journal of Translational Medicine

Figure 2

From: The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Figure 2

Immune responses measured by ELISPOT assay and In vitro T cell proliferation assay. ELISPOT results for patient 7A (panel A), 14 B (panel C), and 11C (panel E) who had positive immune responses to the mutant ras peptide in blue compared with the normal ras peptide in red and the control peptide (tax) in green. Panels B and D show positive T cell proliferative assay responses for patient 7A and 14B, respectively in blue compared with the normal ras peptide in red and the positive control peptide (influenza) in green. Abbreviations: Pre-vaccine, Pre-vaccination sample; Post-V, Post-vaccination sample marked by the vaccine number; f/u, Follow up sample marked in months (ms) from the last post vaccine sample.

Back to article page